Pharmacogenetics to Avoid Adverse Drug Reactions

Pharmacogenetics to Avoid Adverse Drug Reactions

Adverse drug reactions are one of the major constraints when using drugs. These adverse reactions can impact healthcare systems as strongly as many prevalent diseases. Identifying DNA variants associated with adverse drug reactions can help personalize medicine and sustain healthcare systems. This b...

Full description

Bibliographic Details
Format:	eBook
Language:	English
Published:	Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
Subjects:	Medicine (es)citalopram 5-fluorouracil acute coronary syndrome adverse drug reactions adverse events allele anti-epileptic drugs (AEDS) antiepileptics antipsychotic agents atorvastatin capecitabine cardiology cardiovascular disease clinical implementation clopidogrel colorectal cancer cutaneous adverse drug reaction cutaneous adverse drug reactions (CADRs) CYP2C9*3 CYP450 enzymes cytochrome P-450 enzyme system direct oral anticoagulants drug-drug-gene-interaction drug-drug-interaction drug-gene-interaction epistasis fluoropyrimidine genetic polymorphism genetic risk factors genotype guidelines HLA HLA B India n/a personalised medicine pharmacogenetics pharmacogenomics phenytoin (PHT) platelet reactivity polymorphism precision medicine psychotic disorders random forest SCAR single-nucleotide variants SLCO1B1 South India statin the PharmLines initiative thymidylate synthase thymidylate synthase enhancer region toxicity upstream stimulatory factor 1
Online Access:	Open Access: DOAB: description of the publication Open Access: DOAB, download the publication

Similar Items

Genetic Determinants in <i>HLA</i> and Cytochrome P450 Genes in the Risk of Aromatic Antiepileptic-Induced Severe Cutaneous Adverse Reactions
by: Ali Fadhel Ahmed, et al.
Published: (2021-05-01)

Impact of Drug-Gene-Interaction, Drug-Drug-Interaction, and Drug-Drug-Gene-Interaction on (es)Citalopram Therapy: The PharmLines Initiative
by: Muh. Akbar Bahar, et al.
Published: (2020-11-01)

THE SLCO1B1 GENE POLYMORPHISM AND STATIN-INDUCED MYOPATHY IN RUSSIAN PATIENTS
by: V. I. Petrov, et al.
Published: (2014-10-01)

Association of <i>HLA-B*51:01, HLA-B*55:01</i>, <i>CYP2C9*3,</i> and Phenytoin-Induced Cutaneous Adverse Drug Reactions in the South Indian Tamil Population
by: Shobana John, et al.
Published: (2021-07-01)

Association of HLA-A and HLA-B Alleles with Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Thai Population
by: Napatrupron Koomdee, et al.
Published: (2017-11-01)

Rivaroxaban-induced hemorrhage associated with ABCB1 genetic defect
by: Kuntheavy Ing Lorenzini, et al.
Published: (2016-12-01)

Clinical spectrum of cutaneous adverse drug reactions
by: Ankita Agrawal, et al.
Published: (2018-01-01)

CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations—Implication for Drug Safety, Dosing, and Individualized Therapy
by: Immaculate M. Langmia, et al.
Published: (2021-07-01)

A Cross-sectional Study of Acneiform Eruptions at a Tertiary Center
by: Shivaprasad Gouda, et al.
Published: (2021-06-01)

A Retrospective Study of Epidemiological and Clinical Patterns of ACDRs in Goa Medical College over a 6 Year Period
by: Rakhi Ghodge, et al.
Published: (2017-04-01)

Unusual and interesting adverse cutaneous drug reactions
by: Vaishali Masatkar, et al.
Published: (2018-01-01)

Clinical Profile of Adverse Cutaenous Drug Reactions in Patients with Human Immunodeficiency Virus
by: Puteri Nabilah Maharani, et al.
Published: (2020-12-01)

Cutaneous adverse drug reactions in a tertiary care teaching hospital in India: An intensive monitoring study
by: Sejal Thakkar, et al.
Published: (2017-01-01)

Association Between HLA Genotype and Cutaneous Adverse Reactions to Antiepileptic Drugs Among Epilepsy Patients in Northwest China
by: Xu Wang, et al.
Published: (2019-01-01)

Acute generalised exanthematous pustulosis secondary to cotrimoxazole or tenofovir
by: J Black, et al.
Published: (2012-10-01)

Evaluation of potential drug-drug interactions in hospitalized patients at a tertiary care hospital: A pilot study
by: Yesim Kaya Yasar, et al.
Published: (2020-06-01)

Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis
by: Ya-Yen Yu, et al.
Published: (2019-12-01)

Drug Allergy: Delayed Cutaneous Hypersensitivity Reactions to Drugs
by: Rose L. Hamm
Published: (2016-08-01)

Cutaneous reactions due to antihypertensive drugs
by: Upadhayai J, et al.
Published: (2006-01-01)

Fixed-drug eruptions: What can we learn from a case series?
by: Ratinder Jhaj, et al.
Published: (2018-01-01)

HOSPITALIZATIONS DUE TO ADVERSE DRUG EVENTS IN THE ELDERLY – A RETROSPECTIVE REGISTER STUDY
by: Outi Laatikainen, et al.
Published: (2016-10-01)

Tenofovir induced lichenoid drug eruption
by: Mrinal Gupta, et al.
Published: (2015-07-01)

Drug eruptions: An 8-year study including 106 inpatients at a dermatology clinic in Turkey
by: Fatma Akpinar, et al.
Published: (2012-01-01)

The role and histopathology of oral drug challenge in the evaluation of fixed drug eruptions
by: Megan Brinkworth Vissing, et al.
Published: (2021-10-01)

A study of cutaneous adverse drug reactions in a tertiary care center in south India
by: Lakshmi Rajendran, et al.
Published: (2021-01-01)

Pogostone inhibits the activity of CYP3A4, 2C9, and 2E1 in vitro
by: Guiying Zhang, et al.
Published: (2021-01-01)

Anemarsaponin BII inhibits the activity of CYP3A4, 2D6, and 2E1 with human liver microsomes
by: Mingwei Wang, et al.
Published: (2020-01-01)

Metronidazole-Induced Bullous Pemphigoid: A Case Report
by: Saibal Moitra, et al.
Published: (2015-12-01)

Adverse cutaneous drug reactions: Eight year assessment in hospitalized patients
by: Fatemeh Mokhtari, et al.
Published: (2014-01-01)

Controversies in the management of cutaneous adverse drug reactions
by: Yashpal Manchanda, et al.
Published: (2018-01-01)

Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients
by: Galvez JM, et al.
Published: (2018-10-01)

Pharmaceutical systematics: Description and preliminary investigation of an alternative method for structuring drug information
by: Mary E. Kiersma, et al.
Published: (2011-01-01)

Data-driven prediction of adverse drug reactions induced by drug-drug interactions
by: Ruifeng Liu, et al.
Published: (2017-06-01)

Prediction of Severity of Drug-Drug Interactions Caused by Enzyme Inhibition and Activation
by: Alexander Dmitriev, et al.
Published: (2019-10-01)

Potential of drug interactions as a cause of adverse drug reactions in patients with kidney diseases
by: Tahereh Gholipur Shahraki, et al.
Published: (2020-01-01)

Drug interactions in HIV patients treated in a high complexity hospital of Antofagasta city
by: Patricio R. Araya, et al.
Published: (2017-11-01)

Adverse Drug Reactions Associated with CYP 2B6 Polymorphisms in HIV/AIDS-Treated Patients in Yaoundé, Cameroon
by: Nguefeu Nkenfou C, et al.
Published: (2019-12-01)

Concomitant Treatment with Voriconazole and Flucloxacillin: A Combination to Avoid
by: Ruth Van Daele, et al.
Published: (2021-09-01)

The Importance of Computerized Drug Interaction Checker Programs Used in Community Pharmacies to Avoid Potential Drug Interactions: A Preliminary Study with Clarithromycin
by: Abdullah Şimşek, et al.
Published: (2019-01-01)

Drug interaction surveillance using individual case safety reports
by: Strandell, Johanna
Published: (2011)